IHC Antibodies

The gold standard on cancer detection

From antigen design to validation, GenomeMe develops immunohistochemistry (IHC) antibodies targeting the critical markers you need to make your diagnosis with confidence. Expect uncompromising quality at unbeatable prices when you choose GenomeMe.

Why choose GenomeMe?

260+ IHC antibodies
Complete Pathology Portfolio
We are the only company in the world to develop a complete portfolio of 260+ IHC antibodies for clinically significant markers
Unique Markers Under Development
Unique Markers Under Development
Constantly at the leading edge of IHC marker development: ROS1, Pan-TRK, EGFRvIII, etc.
No product discontinuations, and full refund
Guaranteed Peace of Mind
No product discontinuations, and full refund on any order that does not meet you expectations

GeneAb IHC Antibodies

Redefining antibody performance

GeneAb hybridomas are specifically designed, developed, screened, and validated for immunohistochemistry (IHC). Our antibodies are tested by ELISA, WB, IHC and ICC to ensure uncompromising performance in specificity and sensitivity.

Exceeding industry gold standards:
  • Over 300 tissue types (both normal and disease state) tested with each antibody.
  • Immunocytochemistry (ICC) carried out using knock out / knock in cell lines established in house.
  • Strict guidelines for quality assurance in place that meet ISO 13485 and MDSAP requirements.
  • Blind evaluation of each slide is performed by our team of pathologists

What fellow pathologists say about us

"We tried GenomeMe Rabbit PD-L1 [IHC411] antibody because of its amazing price. We compared it side by side with with the Ventana PD-L1 [SP142] and we were even more amazed at its quality - I couldn't believe a PD-L1 stain can be this specific with almost no non-specific staining in lung stromal tissue making the clinical diagnosis so much more simpler."
"You can’t believe the number of times we have called and emailed the technical support team of GenomeMe to help with our onboarding of their complete antibody portfolio. They were always very helpful, resourceful, flexible, and supported us fully till the process was complete!"

Upcoming events

March 16-21, 2019
USCAP 2019
Come visit us at Booth 534 at the upcoming USCAP Conference [March 16-21st, 2019] at the Gaylord National Resort & Convention Center in National Harbor, Maryland
September 7-11, 2019
31st European Congress of Pathology
GenomeMe will be exhibiting at the 31st European Congress of Pathology [September 7-11th, 2019] at the Acropolis Convention Center in Nice, France. Stay tuned for booth information

News and Updates

Genome Me facility in Metro Vancouver
Mar. 3/19
GenomeMe is exhibiting at the USACP 108th Annual Meeting
Come visit us at Booth 534 at the upcoming USCAP Conference [March 19-21st, 2019] at the Gaylord National Resort & Convention Center in National Harbor, Maryland
Genome Me Export Awards British Columbia
Aug. 10/18
GenomeMe is now a finalist in the BC Export Awards in the Emerging Exporter Category
The Emerging Export Awards recognizes a company that has made its initial entry into an export market and achieved notable success. The award acknowledges the company's ability to overcome obstacles in order to expand its potential markets and grow its business through export.